CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine
about
CpG Oligonucleotides as Cancer Vaccine AdjuvantsStructure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery systemProtection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens.Anthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine.In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection modelImmunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvantsApplication of nanotechnologies for improved immune response against infectious diseases in the developing worldThe impact of "omic" and imaging technologies on assessing the host immune response to biodefence agents.TLR-based immune adjuvants.A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations.CpG DNA as a vaccine adjuvant.High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses.Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.TLR9 mediates S. aureus killing inside osteoblasts via induction of oxidative stress.Systemic but not mucosal immunity induced by AVA prevents inhalational anthraxCpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine.CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine.Synthetic oligonucleotides as modulators of inflammationEffect of CpG oligonucleotides on vaccine-induced B cell memory.Immunostimulatory DNA as a vaccine adjuvant.Use of nanoparticles to deliver immunomodulatory oligonucleotides.TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis.Innovative strategies for co-delivering antigens and CpG oligonucleotides.Engineering nano- and microparticles to tune immunityRecombinant Sindbis virus vectors designed to express protective antigen of Bacillus anthracis protect animals from anthrax and display synergy with ciprofloxacin.A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen.Liposome-antigen-nucleic acid complexes protect mice from lethal challenge with western and eastern equine encephalitis viruses.Peptide/protein vaccine delivery system based on PLGA particles.Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective.Recent progress concerning CpG DNA and its use as a vaccine adjuvant.Delivery system for the enhanced efficiency of immunostimulatory nucleic acids.Optimization, Production, and Characterization of a CpG-Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen.CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies.Preparation and characterization of nickel nanoparticles for binding to his-tag proteins and antigens.A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice
P2860
Q26783826-2D99111F-EFE1-46F1-AA47-6D771F5CBD08Q27004381-CDC720E3-1AE5-4E1B-83AA-97F76CA1676CQ33303670-5401408C-12BF-41FC-B254-C72A1DC14DE0Q33505445-2908D4AE-30F0-4FD6-A907-842AF3345079Q33576071-B5005E6C-2AF9-445F-A689-745F410E0A8BQ33698106-1DA6CA8F-3244-46D9-AD58-B44E1C1D677FQ33894321-E597F0B5-7694-46E8-AC5C-3B1AE64A8A70Q34275632-DB4C30D4-342F-4CD0-97A5-A1440FE16A3BQ34400322-B0FB7C24-F470-4105-951B-D05A1CF7BFC4Q34663480-79CC854D-31DB-4A3E-BB2E-4EC7854A62FBQ35025722-9B724365-8E20-4D19-9608-A8974AE7E4D8Q35679560-691128C4-861E-4F75-8640-F5D723F0C74DQ35836140-A98E0802-11D3-4CA5-BD80-4D0E3DE11E8EQ35853440-9811F128-7C98-4C83-A447-28A9E0E03C9BQ36156486-7B1DA43B-8DF9-4C4B-ABBD-6E9E4792DC57Q36226066-DCEF8E64-D572-4812-8BFA-B9B20935D03EQ36530221-D4AD4E55-C76D-45E2-9E44-476935377994Q36673656-5F8E9C8B-DAB6-4643-AD7A-FD26D0F62696Q36882257-C0D35A9A-D108-4C50-910E-CA925A5461BAQ36924602-C1AB0F9D-69AD-4A58-883E-2A13DF1288D8Q36968274-CBC4F145-E1F2-497D-B1F4-2B879B41B753Q36995537-52A33A59-DD97-4324-9036-4F24A1D23A0CQ37120117-000838CD-D149-4B7B-B86C-17179541DED3Q37130626-F352F828-0CFE-4896-A85F-255D3B5926C2Q37205125-EA83C5F7-E355-4316-89DD-C1E797398DF1Q37410033-6730684C-F46D-4160-9C3B-62AE35A4DF00Q37451219-9779CB32-4C58-4767-B464-2D09D9C2C0A2Q37547211-EE45520C-EB92-496F-B834-015AC4F7A649Q37838652-ED8496B5-11BF-4B4F-8776-EC8F2585A0BEQ38066148-79206D8D-A570-4799-B93C-508E26135888Q38168903-83D9B729-223F-4002-9B79-45F4AA1CF738Q39325348-CB10E388-9968-471E-BF19-5D2F72AEBACCQ41966010-959B08FF-1FA3-4CEF-A016-A53D3E74D96CQ43146970-16338A6C-7754-44A7-A665-9152E623C7E2Q45098418-CF421706-A01A-45FB-8EFD-61F39418D07BQ59127186-B734C48F-5DF4-4EB4-99A9-9FDCDB73930F
P2860
CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
CpG oligodeoxynucleotides adso ...... f the licensed anthrax vaccine
@ast
CpG oligodeoxynucleotides adso ...... f the licensed anthrax vaccine
@en
type
label
CpG oligodeoxynucleotides adso ...... f the licensed anthrax vaccine
@ast
CpG oligodeoxynucleotides adso ...... f the licensed anthrax vaccine
@en
prefLabel
CpG oligodeoxynucleotides adso ...... f the licensed anthrax vaccine
@ast
CpG oligodeoxynucleotides adso ...... f the licensed anthrax vaccine
@en
P2093
P2860
P1476
CpG oligodeoxynucleotides adso ...... f the licensed anthrax vaccine
@en
P2093
Bruce E Ivins
Dennis M Klinman
Derek T O'Hagan
Jeffrey B Ulmer
Manmohan Singh
P2860
P304
P356
10.1128/IAI.73.2.828-833.2005
P407
P50
P577
2005-02-01T00:00:00Z